Direct-acting Antiviral in the Treatment of Chronic Hepatitis C: Bonuses and Challenges

Owing to the rapid development and wide clinical application of direct acting antiviral (DAA) drugs in the treatment of hepatitis C virus (HCV) infection, the era of interferon-based therapy has almost come to an end. Cumulative studies show that DAA therapy renders high cure efficiency (>90%) an...

Descripción completa

Detalles Bibliográficos
Autores principales: Zeng, Haiyan, Li, Lei, Hou, Zhouhua, Zhang, Yapeng, Tang, Zhongxiang, Liu, Shuiping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7163356/
https://www.ncbi.nlm.nih.gov/pubmed/32308542
http://dx.doi.org/10.7150/ijms.43079
_version_ 1783523199831506944
author Zeng, Haiyan
Li, Lei
Hou, Zhouhua
Zhang, Yapeng
Tang, Zhongxiang
Liu, Shuiping
author_facet Zeng, Haiyan
Li, Lei
Hou, Zhouhua
Zhang, Yapeng
Tang, Zhongxiang
Liu, Shuiping
author_sort Zeng, Haiyan
collection PubMed
description Owing to the rapid development and wide clinical application of direct acting antiviral (DAA) drugs in the treatment of hepatitis C virus (HCV) infection, the era of interferon-based therapy has almost come to an end. Cumulative studies show that DAA therapy renders high cure efficiency (>90%) and good safety profile, and may even bring some unexpected benefits to the patients. However, some issues of concern arise, one of which is the resistance mutation of HCV genome leading to failure of treatment. With the aim of providing some meaningful references for the treatment of chronic hepatitis C (CHC), this article summarizes the research progress on benefits of DAA accompanied by viral clearance in the treatment of chronic hepatitis and the drug resistance.
format Online
Article
Text
id pubmed-7163356
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Ivyspring International Publisher
record_format MEDLINE/PubMed
spelling pubmed-71633562020-04-17 Direct-acting Antiviral in the Treatment of Chronic Hepatitis C: Bonuses and Challenges Zeng, Haiyan Li, Lei Hou, Zhouhua Zhang, Yapeng Tang, Zhongxiang Liu, Shuiping Int J Med Sci Review Owing to the rapid development and wide clinical application of direct acting antiviral (DAA) drugs in the treatment of hepatitis C virus (HCV) infection, the era of interferon-based therapy has almost come to an end. Cumulative studies show that DAA therapy renders high cure efficiency (>90%) and good safety profile, and may even bring some unexpected benefits to the patients. However, some issues of concern arise, one of which is the resistance mutation of HCV genome leading to failure of treatment. With the aim of providing some meaningful references for the treatment of chronic hepatitis C (CHC), this article summarizes the research progress on benefits of DAA accompanied by viral clearance in the treatment of chronic hepatitis and the drug resistance. Ivyspring International Publisher 2020-03-15 /pmc/articles/PMC7163356/ /pubmed/32308542 http://dx.doi.org/10.7150/ijms.43079 Text en © The author(s) This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
spellingShingle Review
Zeng, Haiyan
Li, Lei
Hou, Zhouhua
Zhang, Yapeng
Tang, Zhongxiang
Liu, Shuiping
Direct-acting Antiviral in the Treatment of Chronic Hepatitis C: Bonuses and Challenges
title Direct-acting Antiviral in the Treatment of Chronic Hepatitis C: Bonuses and Challenges
title_full Direct-acting Antiviral in the Treatment of Chronic Hepatitis C: Bonuses and Challenges
title_fullStr Direct-acting Antiviral in the Treatment of Chronic Hepatitis C: Bonuses and Challenges
title_full_unstemmed Direct-acting Antiviral in the Treatment of Chronic Hepatitis C: Bonuses and Challenges
title_short Direct-acting Antiviral in the Treatment of Chronic Hepatitis C: Bonuses and Challenges
title_sort direct-acting antiviral in the treatment of chronic hepatitis c: bonuses and challenges
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7163356/
https://www.ncbi.nlm.nih.gov/pubmed/32308542
http://dx.doi.org/10.7150/ijms.43079
work_keys_str_mv AT zenghaiyan directactingantiviralinthetreatmentofchronichepatitiscbonusesandchallenges
AT lilei directactingantiviralinthetreatmentofchronichepatitiscbonusesandchallenges
AT houzhouhua directactingantiviralinthetreatmentofchronichepatitiscbonusesandchallenges
AT zhangyapeng directactingantiviralinthetreatmentofchronichepatitiscbonusesandchallenges
AT tangzhongxiang directactingantiviralinthetreatmentofchronichepatitiscbonusesandchallenges
AT liushuiping directactingantiviralinthetreatmentofchronichepatitiscbonusesandchallenges

Ejemplares similares